Comparison of salivary nitric oxide and epidermal growth factor level between diabetic patients and healthy individuals
- 190 Downloads
The purpose of the current study was to compare salivary Nitric oxide and epidermal growth factor level in diabetic patients and healthy individuals. In this paired-control study 20 patients with type 1 diabetes mellitus, 20 patients with type 2 diabetes mellitus and 20 age and sex matched healthy subjects participated. The level of salivary Nitric oxide was increased in type 1 and 2 diabetic patients in comparison to control individuals (P = 0.037 and P = 0.058), respectively. Epidermal growth factor concentration was higher in type 1 and 2 diabetic patients compare to healthy ones, (P = 0.037 and P = 0.005) respectively. There was no significant difference between salivary Nitric oxide and Epidermal growth factor level regarding to the type of diabetes (P > 0.05). Significant statistical correlation was found between Nitric oxide and Epidermal growth factor levels and the fasting blood glucose and HbA1c (P < 0.001). Conclusions: Salivary Nitric oxide and Epidermal growth factor levels were higher in type 1 and type 2 diabetic patients and there was correlation with severity of disease.
KeywordsType 1 diabetes mellitus Type 2 diabetes mellitus Biomarker
This article is a part of thesis supported by Hamadan University of Medical Sciences. We would like to thank Deputy of Education as well as Deputy of Research and Technology of Hamadan University of Medical Sciences for financial support of this study. The authors would like to thank Dr Zeynab Parvizi for English editing of this article.
Conflict of Interests
The authors declare that they have no conflicts of interest.
- 1.Power A. Diabetes mellitus. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson L, et al., editors. Harrison’s principls of internal medicine. 18th ed. New York: McGraw-Hill; 2012. p. 2152–80.Google Scholar
- 3.Liu JDY. Saliva: a potential media for disease diagnostics and monitoring. Oral Oncol. 2012;18.Google Scholar
- 4.Marletta MA. Nitric oxide synthase structure and mechanism. J Biol Chem. 1993;269:12231–4.Google Scholar
- 13.Abu-Saleh N, Ovcharenko E, Awad H, et al. Involvement of the endothelin and nitric oxide systems in the pathogenesis of renal ischemic damage in an experimental DM model. Life Sci. 2012;17.Google Scholar
- 18.Lee HY, Yea K, Kim J, et al. Epidermal growth factor increases insulin secretion and lowers blood glucose in DM mice. J Cell Mol Med. 2008;12:1593–604.Google Scholar
- 19.Yu H, Sun Z, Cui J, et al. Epidermal growth factor and gastrin on PDX1 expression in experimental type 1 DM rats. Am J Med Sci. 2012;343:141–5.Google Scholar
- 20.Loukovaara M, Leinonen P, Teramo K, et al. DM pregnancy associated with increased epidermal growth factor in cord serum at term. Obstet Gynecol. 2004;103:240–4.Google Scholar
- 21.Lao G, Yan L, Yang C, et al. Controlled release of epidermal growth factor from hydrogels accelerates wound healing in DM rats. J Am Podiatr Med Assoc. 2012;102:89–98.Google Scholar
- 23.WHO. The use and interpretation of anthropometry. Geneva: WHO; 1995.Google Scholar
- 29.Mocada S, Palmer R, Higgs EA. Nitric oxide, physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–42.Google Scholar
- 31.Abdollahi M, Zadehkabir R, Rahmat-jirdeh N, et al. Interaction of L-arginine/nitric oxide system with lead acetate on secretion of amylase from isolated rat parotid glands. DARU. 2001;1:50–7.Google Scholar
- 43.Knighton D R, Fiegel VD. Growth factor and comprehensive surgical care of DM wounds. Curr Opin Gen Surg. 1993;32–9.Google Scholar